These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28560484)

  • 1. A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.
    Pantham G; Post A; Venkat D; Einstadter D; Mullen KD
    Dig Dis Sci; 2017 Aug; 62(8):2166-2173. PubMed ID: 28560484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.
    Bajaj JS; Sanyal AJ; Bell D; Gilles H; Heuman DM
    Aliment Pharmacol Ther; 2010 May; 31(9):1012-7. PubMed ID: 20136802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
    Rahimi RS; Singal AG; Cuthbert JA; Rockey DC
    JAMA Intern Med; 2014 Nov; 174(11):1727-33. PubMed ID: 25243839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.
    Sharma P; Sharma BC
    Saudi J Gastroenterol; 2011; 17(2):138-41. PubMed ID: 21372353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
    Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.
    Frenette CT; Levy C; Saab S
    Dig Dis Sci; 2022 Jun; 67(6):1994-2004. PubMed ID: 34169435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC; Sharma P; Agrawal A; Sarin SK
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
    De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
    Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.